Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

Novo Nordisk's (NVO) weight loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries who are both obese and have cardiovascular disease, could cost the system up to $145B ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

How the change could impact Novo Nordisk. The amount Medicare spent on Ozempic, Wegovy, and Rybelsus between November 2023 and October 2024 represents roughly 36% of Wall Street's consensus ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

How the change could impact Novo Nordisk. The amount Medicare spent on Ozempic, Wegovy, and Rybelsus between November 2023 and October 2024 represents roughly 36% of Wall Street's consensus ...